- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe eosinophilic asthma
- Meeting Date: July 2026
Depemokimab – July 2026
- Solution for subcutaneous injection 100 mg in 1 mL
Public Summary Documents
Last updated
13 November 2026
